.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Boehringer Ingelheim
UBS
Harvard Business School
Farmers Insurance
US Department of Justice
McKinsey
Queensland Health
Dow
Merck

Generated: December 14, 2017

DrugPatentWatch Database Preview

SUPRENZA Drug Profile

« Back to Dashboard

Which patents cover Suprenza, and what generic alternatives are available?

Suprenza is a drug marketed by Citius Pharms and is included in one NDA. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has fourteen patent family members in ten countries.

The generic ingredient in SUPRENZA is phentermine hydrochloride. There are seventeen drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the phentermine hydrochloride profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Citius PharmsSUPRENZAphentermine hydrochlorideTABLET, ORALLY DISINTEGRATING;ORAL202088-001Jun 13, 2011DISCNNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Citius PharmsSUPRENZAphentermine hydrochlorideTABLET, ORALLY DISINTEGRATING;ORAL202088-002Jun 13, 2011DISCNNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Citius PharmsSUPRENZAphentermine hydrochlorideTABLET, ORALLY DISINTEGRATING;ORAL202088-001Jun 13, 2011DISCNNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Citius PharmsSUPRENZAphentermine hydrochlorideTABLET, ORALLY DISINTEGRATING;ORAL202088-002Jun 13, 2011DISCNNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Citius PharmsSUPRENZAphentermine hydrochlorideTABLET, ORALLY DISINTEGRATING;ORAL202088-003Mar 27, 2012DISCNNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Citius PharmsSUPRENZAphentermine hydrochlorideTABLET, ORALLY DISINTEGRATING;ORAL202088-003Mar 27, 2012DISCNNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for SUPRENZA

Drugname Dosage Strength RLD Submissiondate
phentermine hydrochlorideOrally Disintegrating Tablets37.5 mgSuprenza3/22/2013
phentermine hydrochlorideOrally Disintegrating Tablets15 mg and 30 mgSuprenza10/19/2012

International Patent Family for Tradename: SUPRENZA

Country Document Number Estimated Expiration
Japan4947833► Subscribe
European Patent Office2254558► Subscribe
Portugal1001748► Subscribe
Germany69834255► Subscribe
Spain2263216► Subscribe
European Patent Office2278590► Subscribe
Denmark1001748► Subscribe
European Patent Office1001748► Subscribe
World Intellectual Property Organization (WIPO)9904758► Subscribe
Japan2001510785► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
UBS
Fish and Richardson
Queensland Health
Novartis
Teva
Julphar
US Army
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot